Zydus buys Zoetis' select brands and Haridwar plant

In a major strategic move to give a boost to its animal health business, Zydus Group has acquired select brands and the manufacturing operations in Haridwar of Zoetis, a global animal health company. The acquisition will help Zydus expand its animal health business in India and gain access to manufacturing operations which have also been catering to global markets. The financial details of the deal remain undisclosed.
 
“We believe that this strategic acquisition will strengthen our portfolio of brands and add new dimensions to our growth in the animal health business. We see this as an opportunity to catapult our business to higher levels of excellence,” commented Pankaj Patel, chairman and managing director, Zydus Cadila.
   
As a result of this acquisition, Zydus gains access to a wide range of nutrition as well as therapeutic products which have strong brand equity and a combined turnover of Rs 171 crore. A major boost to Zydus’ portfolio would be the addition of livestock farmcare products which are well accepted in the market. Zydus’ access to the WHO GMP approved manufacturing facility is expected to boost its exports and institutional business. The plant spread over 10,000 sq m manufactures tablets, liquid orals and injectables.
 
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s  leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines among others in India.